HL7 Terminology (THO)
7.1.0 - Continuous Process Integration (ci build) International flag

HL7 Terminology (THO), published by HL7 International - Vocabulary Work Group. This guide is not an authorized publication; it is the continuous build for version 7.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/UTG/ and changes regularly. See the Directory of published versions

ValueSet: ActSubstanceAdminSubstitutionCode

Official URL: http://terminology.hl7.org/ValueSet/v3-ActSubstanceAdminSubstitutionCode Version: 3.0.0
Responsible: Health Level Seven International Computable Name: ActSubstanceAdminSubstitutionCode
Other Identifiers: OID:2.16.840.1.113883.1.11.16621

Copyright/Legal: This material derives from the HL7 Terminology THO. THO is copyright ©1989+ Health Level Seven International and is made available under the CC0 designation. For more licensing information see: https://terminology.hl7.org/license.html

No description

References

Logical Definition (CLD)

Language: en

This value set includes codes based on the following rules:

This value set excludes codes based on the following rules:

 

Expansion

Expansion performed internally based on codesystem Substance Admin Substitution v4.0.0 (CodeSystem)

This value set contains 9 concepts

SystemCodeDisplay (en)DefinitionJSONXML
http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution  Eequivalent

Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product.

http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution  ECequivalent composition

Substitution occurred or is permitted with another product that is a:

  • pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester
  • pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration

Examples:

  • Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate
  • Pharmaceutical equivalent: Lisonpril for Zestril
http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution  BCbrand composition

Substitution occurred or is permitted between equivalent Brands but not Generics

Examples:

  • Zestril for Prinivil
  • Coumadin for Jantoven
http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution  Ggeneric composition

Substitution occurred or is permitted between equivalent Generics but not Brands

Examples:

  • Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)
http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution  TEtherapeutic alternative

Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile.

Examples:

  • ranitidine for Tagamet
http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution  TBtherapeutic brand

Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics

Examples:

  • Zantac for Tagamet
http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution  TGtherapeutic generic

Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands

Examples:

  • Ranitidine for cimetidine
http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution  Fformulary

This substitution was performed or is permitted based on formulary guidelines.

http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution  Nnone

No substitution occurred or is permitted.

Description of the above table(s).

History

DateActionCustodianAuthorComment
2023-11-14reviseTSMGMarc DuteauAdd standard copyright and contact to internal content; up-476
2022-10-18reviseTSMGMarc DuteauFixing missing metadata; up-349
2020-05-06reviseVocabulary WGTed KleinMigrated to the UTG maintenance environment and publishing tooling.
2014-03-26revise2014T1_2014-03-26_001283 (RIM release ID)Vocabulary (Woody Beeler) (no record of original request)Lock all vaue sets untouched since 2014-03-26 to trackingId 2014T1_2014_03_26